Evidence map›Paper›PMID 34815425›Full record

ArticleScientific reports2021

Evaluation of selected IL6/STAT3 pathway molecules and miRNA expression in chronic obstructive pulmonary disease.

J M Kiszałkiewicz, S Majewski, W J Piotrowski, P Górski, D Pastuszak-Lewandoska, M Migdalska-Sęk, E Brzeziańska-Lasota

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Plants (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Article
  10. [Comparison of anti-inflammatory, antibacterial and analgesic activities of formulated granulesNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. PARP Inhibitors in Colorectal Malignancies: A 2023 Update.Reviews on recent clinical trials · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

J M Kiszałkiewicz *Department of Biomedicine and Genetics, Chair of Biology and Medical Microbiology, Medical University of Lodz, St. Pomorska 251, 92-213, Lodz, Poland. justyna.kiszalkiewicz@umed.lodz.pl.
S Majewski *Department of Pneumology, Medical University of Lodz, St. Kopcińskiego 22, 90-153, Lodz, Poland.
W J PiotrowskiDepartment of Pneumology, Medical University of Lodz, St. Kopcińskiego 22, 90-153, Lodz, Poland.
P GórskiDepartment of Pneumology, Medical University of Lodz, St. Kopcińskiego 22, 90-153, Lodz, Poland.
D Pastuszak-LewandoskaDepartment of Microbiology and Laboratory Medical Immunology, Chair of Biology and Medical Microbiology, Medical University of Lodz, St. Pomorska 251, 92-213, Lodz, Poland.
M Migdalska-SękDepartment of Biomedicine and Genetics, Chair of Biology and Medical Microbiology, Medical University of Lodz, St. Pomorska 251, 92-213, Lodz, Poland.
E Brzeziańska-LasotaDepartment of Biomedicine and Genetics, Chair of Biology and Medical Microbiology, Medical University of Lodz, St. Pomorska 251, 92-213, Lodz, Poland.
Medical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COPD has been regarded as a global epidemic due to an increase in pollution and tobacco exposure. Therefore, the study of molecular mechanism as the basis for modern therapy is important. The aim of the study was the assessment of gene expression levels, IL-6, IL-6ST, PIAS3, STAT3, and miRNAs, miRNA-1, miRNA-106b, miRNA-155, in patients with COPD. Induced sputum as well as PBMC were collected from 40 patients clinically verified according to the GOLD 2021 (A-D) classification and from the control group (n = 20). The levels of gene and miRNA expression were analysed by qPCR. In induced sputum IL6 was significantly down-regulated in COPD group compared with control (p = 0.0008), while IL6ST were up-regulated (p = 0.05). The results were also statistically significant for STAT3 (p = 0.04) and miRNA-155 (p = 0.03) with higher expression in the current smokers compared to ex-smokers. Higher expression levels for IL6ST (p = 0.03) in COPD patients with the exacerbation history compared to COPD patients without the exacerbation history were noted. Compared induced sputum and PB lymphocytes we observed higher expression of IL6 (p = 0.0003), STAT3 (p = 0.000001) miRNA-106b (p = 0.000069 and miRNA-155 (p = 0.000016) in induced sputum with lower expression of PIAS3 (p = 0.006), IL6ST (p = 0.002) and miRNA-1 (p = 0.001). Differences in gene expression levels of the IL-6/IL6ST/STAT3 pathway and miRNA depending on the smoking status and classification of patients according to GOLD suggest the importance of these genes in the pathogenesis of COPD and may indicate their potential utility in monitoring the course of the disease.

Indexed as

AgedCase-Control StudiesFemaleHumansInterleukin-6MaleMicroRNAsMiddle AgedMolecular ChaperonesProtein Inhibitors of Activated STATPulmonary Disease, Chronic ObstructiveSputumSTAT3 Transcription FactorIL6 protein, humanInterleukin-6MicroRNAsMIRN106 microRNA, humanMIRN155 microRNA, humanMolecular ChaperonesPIAS3 protein, humanProtein Inhibitors of Activated STATSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID34815425
PMCPMC8610981
OpenAlexW3217678124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.